Xanax XR, also known by its generic name alprazolam, is a benzodiazepine prescribed to treat panic disorder and generalized ...

Bottles of Xanax – one of the most widely-prescribed medications for anxiety – have been recalled after failing a quality ...

Lea Didion didn’t realize the night sweats she began experiencing in her 40s might be a sign of perimenopause. Her doctor ...

In a report released today, Glen Santangelo from Barclays maintained a Buy rating on Viatris, with a price target of $17.00. Santangelo covers the Healthcare sector, focusing on stocks such as Teva ...

Vasoplegia is defined as sustained low systemic vascular resistance in the context of a normal or high cardiac index, leading ...

Viatris Inc. (NASDAQ:VTRS) is one of the 13 extreme value stocks to buy now. Viatris Inc. (NASDAQ:VTRS) is covered by 12 analysts on Wall Street with a medium price target of $16, suggesting 12.36% ...

Shares of Viatris Inc. VTRS slipped 1.03% to $13.47 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.11% to 6,816.89 and Dow ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Viatris Inc. closed 16.03% short of its 52-week high of $16.47, which the company achieved on February 26th.

Viatris (VTRS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Viatris ( (VTRS)) has shared an update. On November 6, 2025, Viatris reported strong financial results for the third quarter of 2025, with total revenues aligning with expectations. The company made ...